Aethlon Medical (NASDAQ:AEMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report published on Saturday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright cut their target price on shares of Aethlon Medical from $10.00 to $7.00 and set a buy rating for the company in a research report on Monday, June 24th.

Aethlon Medical Price Performance

AEMD stock opened at $0.36 on Friday. The stock has a market capitalization of $4.98 million, a P/E ratio of -0.07 and a beta of 1.72. Aethlon Medical has a 1-year low of $0.24 and a 1-year high of $2.60. The business has a fifty day moving average price of $0.39 and a 200-day moving average price of $0.82.

Aethlon Medical (NASDAQ:AEMD) last posted its earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.10. During the same quarter in the prior year, the firm posted ($1.30) EPS. As a group, analysts anticipate that Aethlon Medical will post -1.1 earnings per share for the current year.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.